Fingerprinting Drug Screening System to Be Used for Fentanyl Testing
Intelligent Bio Solutions Inc. has announced plans to add fentanyl to the substances detected by its Fingerprinting Drug Screening System.
Intelligent Bio Solutions Inc. has announced plans to add fentanyl to the substances detected by its Fingerprinting Drug Screening System.
UTI complications are common for pregnant women and newborns, and is critical to accurately diagnose and treat patients.
The March/April 2022 Tech Guide that appears in Clinical Lab Products (CLP) features a wide-range of products from top laboratory providers.
Promis Diagnostics recently presented data for CystoChek, a proprietary urine-based DNA methylation test of PENK for bladder cancer detection in hematuria.
Read MoreTo measure urine sugar levels in elderly or long-term care patients, sensors can be embedded directly into their diapers.
Read MoreCarolina Liquid Chemistries Corp. has launched MyPOCtest.com, an e-commerce website to help supply medical facilities with POC rapid tests.
Read MorePatients undergoing surgery and other procedures are routinely pre-screened for UTIs, but the vast majority of these tests are not needed.
Read MoreADXBLADDER, a urinary biomarker test for bladder cancer, is currently undergoing clinical trials in the U.S.
Read MoreThe FDA awarded AnchorDx a Breakthrough Device Designation for UriFind, an early detection test for bladder cancer based on urine DNA methylation detection.
Read MoreMIT engineers have created a diagnostic nanoparticle that can identify cancer through a urine test and act as an imaging agent, pinpointing the tumor location.
Read MoreNew Jersey Urology (NJU) unveiled its newly renovated pathology laboratory, which offers a menu of services, including NGS and PCR testing.
Read MoreThe urine test, which is expected to be available by mid-2022, will use highly sensitive liquid biopsy technology developed by Nonacus and a panel of biomarkers validated by Birmingham University researchers to diagnose bladder cancer.
Read MoreMagellan Diagnostics is recalling its LeadCare II, LeadCare Plus, and LeadCare Ultra Blood Lead Tests due to a significant risk of falsely low results. The FDA has deemed it a Class I recall.
Read MoreA recent study by Nagoya University researchers revealed that microRNAs in urine could be a promising biomarker to diagnose brain tumors.
Read MoreBD has announced the US launch of a urine culture application for use with the BD Kiestra lab automation incubation and imaging system.
Read MoreThe Tech Guide from the March/April 2021 issue of Clinical Lab Products includes urinalysis and toxicology analyzers from Abbott, Arkray USA, Beckman Coulter, Cardinal Health, MedTox Diagnostics, Quidel, and Sysmex America.
Read MoreI-O Urology’s CarePath technology increases engagement, improves compliance, and standardizes treatment pathways for patients with lower urinary tract symptoms.
Read MoreA urine test could have avoided one-third of unnecessary prostate cancer biopsies while failing to detect only a small number of cancers, according to a validation study.
Read More